I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19

 I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19

I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19

  • The initiation of clinical study follows the US FDA’s acceptance of IND for TJM2 (TJ003234). The study will explore the potential of TJM2 and initially be conducted in the US and is expected to expand in other countries
  • The company has successfully completed its P-I SAD study, which demonstrated favorable safety, tolerability, PK/PD, and immunogenicity profile of TJM2.
  • TJM2 is mAb targeting GM-CSF, acts by blocking its binding to its receptor hereby preventing downstream signaling and target cell activation and has received NMPA’s IND for P-Ib study in patients with RA. TJM2 is expected to be the first Ab of its class to enter clinical studies in China in 2020

Click here ­to­ read full press release/ article | Ref: Business wire | Image: I-Mab

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post